BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 32967920)

  • 1. Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion.
    Baruchel A; Brown P; Rizzari C; Silverman L; van der Sluis I; Wolthers BO; Schmiegelow K
    ESMO Open; 2020 Sep; 5(5):e000977. PubMed ID: 32967920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open-Cancer Horizons roundtable discussion.
    Burke PW; Hoelzer D; Park JH; Schmiegelow K; Douer D
    ESMO Open; 2020 Oct; 5(5):e000858. PubMed ID: 33037033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study.
    Wolthers BO; Frandsen TL; Baruchel A; Attarbaschi A; Barzilai S; Colombini A; Escherich G; Grell K; Inaba H; Kovacs G; Liang DC; Mateos M; Mondelaers V; Möricke A; Ociepa T; Samarasinghe S; Silverman LB; van der Sluis IM; Stanulla M; Vrooman LM; Yano M; Zapotocka E; Schmiegelow K;
    Lancet Oncol; 2017 Sep; 18(9):1238-1248. PubMed ID: 28736188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol.
    Raja RA; Schmiegelow K; Albertsen BK; Prunsild K; Zeller B; Vaitkeviciene G; Abrahamsson J; Heyman M; Taskinen M; Harila-Saari A; Kanerva J; Frandsen TL;
    Br J Haematol; 2014 Apr; 165(1):126-33. PubMed ID: 24428625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity as a predictor of treatment-related toxicity in children with acute lymphoblastic leukaemia.
    Egnell C; Heyman M; Jónsson ÓG; Raja RA; Niinimäki R; Albertsen BK; Schmiegelow K; Stabell N; Vaitkeviciene G; Lepik K; Harila-Saari A; Ranta S
    Br J Haematol; 2022 Mar; 196(5):1239-1247. PubMed ID: 34726257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia.
    Gottschalk Højfeldt S; Grell K; Abrahamsson J; Lund B; Vettenranta K; Jónsson ÓG; Frandsen TL; Wolthers BO; Marquart HV; Vaitkeviciene G; Lepik K; Heyman M; Schmiegelow K; Albertsen BK
    Blood; 2021 Apr; 137(17):2373-2382. PubMed ID: 33150360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asparaginase-Associated Pancreatitis in Pediatric Patients with Acute Lymphoblastic Leukemia: Current Perspectives.
    Gibson A; Hernandez C; Tejada FNH; Kawedia J; Rytting M; Cuglievan B
    Paediatr Drugs; 2021 Sep; 23(5):457-463. PubMed ID: 34351604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia.
    Rank CU; Lynggaard LS; Als-Nielsen B; Stock W; Toft N; Nielsen OJ; Frandsen TL; Tuckuviene R; Schmiegelow K
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013399. PubMed ID: 33038027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and risk factors for Central Nervous System thrombosis in paediatric acute lymphoblastic leukaemia during intensive asparaginase treatment: a single-centre cohort study.
    Duarte X; Esteves S; Neto AM; Pereira F
    Br J Haematol; 2016 Jul; 174(2):280-91. PubMed ID: 27018199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age.
    Rank CU; Wolthers BO; Grell K; Albertsen BK; Frandsen TL; Overgaard UM; Toft N; Nielsen OJ; Wehner PS; Harila-Saari A; Heyman MM; Malmros J; Abrahamsson J; Norén-Nyström U; Tomaszewska-Toporska B; Lund B; Jarvis KB; Quist-Paulsen P; Vaitkevičienė GE; Griškevičius L; Taskinen M; Wartiovaara-Kautto U; Lepik K; Punab M; Jónsson ÓG; Schmiegelow K
    J Clin Oncol; 2020 Jan; 38(2):145-154. PubMed ID: 31770057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.
    Hijiya N; van der Sluis IM
    Leuk Lymphoma; 2016; 57(4):748-57. PubMed ID: 26457414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful management of severe L-asparaginase-associated pancreatitis by continuous regional arterial infusion of protease inhibitor and antibiotic.
    Morimoto A; Imamura T; Ishii R; Nakabayashi Y; Nakatani T; Sakagami J; Yamagami T
    Cancer; 2008 Sep; 113(6):1362-9. PubMed ID: 18661511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia.
    Earl M
    Clin Adv Hematol Oncol; 2009 Sep; 7(9):600-6. PubMed ID: 20020672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis.
    Kearney SL; Dahlberg SE; Levy DE; Voss SD; Sallan SE; Silverman LB
    Pediatr Blood Cancer; 2009 Aug; 53(2):162-7. PubMed ID: 19405141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-asparaginase (Leunase) induced pancreatitis in childhood acute lymphoblastic leukemia.
    Sahu S; Saika S; Pai SK; Advani SH
    Pediatr Hematol Oncol; 1998; 15(6):533-8. PubMed ID: 9842647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does octreotide prevent L-asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia?
    Tokimasa S; Yamato K
    Br J Haematol; 2012 May; 157(3):381-2. PubMed ID: 22145577
    [No Abstract]   [Full Text] [Related]  

  • 18. Premedication prior to PEG-asparaginase is cost-effective in pediatric patients with acute lymphoblastic leukemia.
    McCormick M; Lapinski J; Friehling E; Smith K
    Pediatr Blood Cancer; 2021 Aug; 68(8):e29051. PubMed ID: 33860989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of asparaginase discontinuation on outcomes of children with acute lymphoblastic leukaemia receiving the Japan Association of Childhood Leukaemia Study ALL-02 protocol.
    Ishida H; Imamura T; Tatebe Y; Ishihara T; Sakaguchi K; Suenobu S; Sato A; Hashii Y; Deguchi T; Takahashi Y; Hasegawa D; Miyamura T; Iguchi A; Kato K; Saito-Moriya A; Hara J; Horibe K
    Br J Haematol; 2023 Jun; 201(6):1200-1208. PubMed ID: 36891758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical summary of pediatric acute lymphoblastic leukemia patients complicated with asparaginase-associated pancreatitis in SCCLG-ALL-2016 protocol.
    Wang J; Jia WG; Yang LH; Kuang WY; Huang LB; Chen HQ; Wang LN; Zhou DH; Liao N
    Hematology; 2023 Dec; 28(1):2171723. PubMed ID: 36752506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.